New York University · BiologyThe KRAS Innovation Lab
Thales Papagiannakopoulos · New York, New York
Research Focus
Thales Papagiannakopoulos's lab focuses on understanding and treating aggressive forms of lung cancer driven by KRAS mutations, particularly those with mutations in the KEAP1 gene. They explore novel therapeutic strategies that target specific metabolic vulnerabilities and immune evasion mechanisms in these tumors, aiming to improve treatment options for patients with KRAS mutant lung cancer.
lung cancerKRAS mutationKEAP1glutamine metabolismimmunotherapylipocalin 2targeted therapyCRISPR/Cas9precision medicine
Research Aims
4AIM 01Characterize metabolic vulnerabilities in KRAS-driven lung cancer cells.
AIM 02Develop therapies targeting LCN2 to improve anti-tumor immune responses.
AIM 03Assess the efficacy of glutamine antagonists in KEAP1 mutant lung cancer models.
AIM 04Investigate the microenvironment's role in tumor growth influenced by stress responses.
Skills the Lab Values
CRISPR/Cas9genetically engineered mouse modelsmetabolic analysisimmunotherapy techniquescell cultureantibody developmenttumor microenvironment assessmentpre-clinical modelingdrug testing protocols
Output against the department
Publications227top 27% of dept.280th of 1,033
this lab
most publishedleast published
Citations13ktop 28% of dept.290th of 1,033
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.